Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
Go back to Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy| Bold Energy, Inc. (NASDAQ: BOLD) | Delayed: 2.52 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.52 | 52 Week High | $20.74 | |||
| Open | $2.52 | 52 Week Low | $13.06 | |||
| Day High | $2.58 | P/E | N/A | |||
| Day Low | $2.45 | EPS | $0.00 | |||
| Volume | 375,389 | |||||
